Quest Acquires ‘Select Assets’ of Fresenius Medical Care

By Robert Michel | From the Volume XXXII, No. 4 – March 10, 2025 Issue

FRESENIUS MEDICAL CARE AND QUEST DIAGNOSTICS AGREED TO A DEAL in which Quest will provide laboratory testing services for the latter’s dialysis clinics in the United States. Separately, Quest Diagnostics will acquire “select assets” of Spectra Labora…

Read More

---

OIG Issues New Report on Medicare 2023 Lab Spend

By Robert Michel | From the Volume XXXII, No. 2 – January 27, 2025 Issue

CEO SUMMARY: When the Office of the Inspector General (OIG) at the Department of Health and Human Services (HHS) issued its latest report on Medicare spending in 2023 for clinical laboratory tests, it attracted relatively little attention from the lab industry. Maybe other issues—such a…

Read More

---

January 27, 2025, Intelligence: Late-Breaking Lab News

By Robert Michel | From the Volume XXXII, No. 2 – January 27, 2025 Issue

On Jan. 16, 2025, Paul Mango died at the age of 65. With his passing, the profession of laboratory medicine lost an ally and a friend. In the mid-1990s, while at the Institute for Transfusion Medicine in Pittsburgh, Mango convinced the CEOs of 40 hospitals to collaborate and create t…

Read More

---

Global IVD Companies Issue Third Quarter 2024 Earnings

By Robert Michel | From the Volume XXXI, No. 16 – November 25, 2024 Issue

HERE IS A SUMMARY OF THE THIRD QUARTER FINANCIAL PERFORMANCE of t…

Read More

---

Insights from Q3 2024 Earnings Calls Point to a More Robust Lab Market

By Robert Michel | From the Volume XXXI No. 15 – November 4, 2024 Issue

FOR THE THIRD QUARTER OF 2024 (Q3 2024), both of the nation’s largest publicly traded laboratories—Labcorp…

Read More

---

Federal Cases against Labs Result in Convictions

By Robert Michel | From the Volume XXXI, No. 14 – October 14, 2024 Issue

CEO SUMMARY: Over the past 24 months, federal prosecutors have announced a steady parade of criminal convictions, guilty pleas, and settlement agreements involving fraud and clinical laboratory testing. Not only are these cases numerous, but some resolve legal actions initiated by the fed…

Read More

---

Global IVD Companies Report Second Quarter 2024 Earnings

By Robert Michel | From the Volume XXXI, No. 13 – September 23, 2024 Issue

IN THE SECOND QUARTER OF 2024, in vitro diagnostics (IVD) companies reported solid revenues as well as new tests, analyzers, and automation. Most of the IVD companies boosted diagnostic sales in low single digit amounts. During the earnings calls, financial analysts asked company leade…

Read More

---

How Is COVID-19 Evolving? It’s Not Like Flu or Colds

By Robert Michel | From the Volume XXXI, No. 11 – August 12, 2024 Issue

CEO SUMMARY: It’s been 53 months since the SARS-CoV-2 virus triggered the worst global pandemic since 1918’s influenza pandemic. The coronavirus continues to surprise public health officials as new variants are detected, along with a multi-year pattern of summer surges in new cases. T…

Read More

---

Identifying Current Lab Trends from Labcorp & Quest Experience

By Robert Michel | From the Volume XXXI, No. 11 – August 12, 2024 Issue

CEO SUMMARY: Many different factors influence the operations of clinical laboratories in the United States today. One good source of competitive business intelligence is for lab administrators to follow the quarterly earnings calls of the nation’s two biggest public lab corporations. Wi…

Read More

---

2023 Ranking of the World’s Top 13 IVD Corporations

By Robert Michel | From the Volume XXXI, No. 10 – July 22, 2024 Issue

BASED ON 2023 DIAGNOSTICS-RELATED REVENUE, four in vitro diagnostics (IVD) manufacturers continued to lead the global IVD market just as they did in 2022. They are: Thermo Fisher Scientific, Inc., Roche Holdings, Abbott Laboratories, and Danaher Corporation. Th…

Read More

---